bearish
Ascletis Pharma: Reiterate Sell, 29% Downside
389 Views13 Feb 2020 17:22
We have previously discussed the short idea of Ascletis Pharma. Today the stock reacted positively to the news that it received approval from the...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- My EG (MyEG): A Move to Become Regional Player22 Feb 2020
- HK - Tencent, Ping An, SMIC, Xiaomi Lead Shorts; Covering on Alibaba, AIA, HSBC, HKEX21 Feb 2020
- HK - Shorts Pile Into Tencent, CCB, Ping An, Sunny Optical, AIA; Cover Mobile, China Tower, BYD14 Feb 2020
- Ascletis Pharma: Sell the Hype Of (Possible) Coronavirus Clinical Trial05 Feb 2020
- Ascletis Pharma (歌礼制药) Post-Listing: Thoughts on Liquidity and Bull Cases06 Aug 2018
x